BNC-105

Other Medications

Description

BNC-105 is an investigational medication currently being studied in clinical trials for colorectal cancer. It is being evaluated as part of a combination therapy with nivolumab (an immunotherapy drug) for patients with microsatellite stable (MSS) colorectal cancer that cannot be removed by surgery and has not responded to previous treatments. The trial aims to see if BNC-105, when used with nivolumab, can improve outcomes in this specific group of patients. BNC-105 is being studied in Phase 2 trials.

Mechanism of Action

BNC-105 is being investigated for its potential to affect the tumor microenvironment. The specific way it works (its molecular target or mechanism of action) is still being characterized in clinical trials. It is being studied in combination with nivolumab, which is an immunotherapy that helps the body's immune system fight cancer.

Side Effects

As BNC-105 is an investigational drug in early-phase trials Its side effect profile is still being evaluated. The most common side effects observed in the clinical trial (NCT03647839) are likely related to the combination therapy Including nivolumab. These may include fatigue Diarrhea Rash Decreased appetite Nausea Cough And musculoskeletal pain. Specific side effects related solely to BNC-105 are still being determined in ongoing studies.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT03647839 Phase 2

Archived

Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer

Australia

Quick Info

Category	Other Medications
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.